English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

: dislipemia prevalence in type 2 diabetes is very often, between 35 to 56%; and despite new therapeutic options, statins continue being the drugs of first choice for treatment. Objectives : analyze the possible pharmacological interactions between statins and non-insulin drugs used in type 2 diabetic patients to normalize blood glucose. Inhibition of statins on HMG-CoA is highly selective, so pharmacodynamic interactions are not expected. But regarding pharmacokinetics, there are several levels where interactions with other drugs may occur. Three main levels of pharmacokinetic interactions have been described so far: membrane transporter OATP1B1, cytochrome P450 and absorption.

INTERACCIONES FARMACOLÓGICAS DE ESTATINAS CON AGENTES ANTIDIABÉTICOS NO INSULÍNICOS